share_log

EF Hutton Reiterates Buy on Pasithea Therapeutics, Maintains $2 Price Target

EF Hutton Reiterates Buy on Pasithea Therapeutics, Maintains $2 Price Target

EF Hutton 重申买入 Pasithea Therapeutics,维持2美元的目标股价
Benzinga ·  2023/07/10 12:15

EF Hutton analyst Elemer Piros reiterates Pasithea Therapeutics (NASDAQ:KTTA) with a Buy and maintains $2 price target.

EF Hutton分析师Elemer Piros重申Pasithea治疗公司(纳斯达克:KTTA)为Buy,并维持2美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发